AIM ImmunoTech Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas K. Equels
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2117 SW Highway 484 Ocala FL United States of America 34473
- IPO Date
- Nov 2, 1995
- CIK
- 0000946644
- Website
- aimimmuno.com
- Similar Companies
- Business
- AIM ImmunoTech Inc. is a leading immuno-pharmaceutical company dedicated to the research and development of innovative therapies for a variety of cancers, viral infections, and immune system disorders. The company's flagship investigational drug, Ampligen (rintatolimod), is a synthetic double-stranded RNA molecule operating as a Toll-like Receptor 3 (TLR3) agonist. Ampligen is being explored in multiple clinical trials for various solid tumor cancers, including a primary focus on metastatic pancreatic cancer, where it is being evaluated in combination with other immunotherapies. It is also undergoing assessment for applications in conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID conditions, with positive preliminary data reported in these areas. Ampligen is commercially approved in Argentina for treating severe chronic fatigue syndrome. Beyond Ampligen, the company offers Alferon N Injection, a natural alpha interferon formulation approved for treating refractory genital warts. AIM ImmunoTech actively engages in strategic collaborations with major cancer research centers and has secured patents for Ampligen's use in combination therapies for various cancers and for long-COVID treatments in key markets like Japan and Europe. Headquartered in Ocala, Florida, the company, formerly known as Hemispherx Biopharma, Inc., rebranded to AIM ImmunoTech Inc. in 2019, reflecting its core mission in amplified immunological modulation. The company continues to advance its pipeline with an emphasis on addressing unmet medical needs in oncology and debilitating chronic conditions.
Company News
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years
Digitalbox eyes creator-led growth as it rides out Meta disruption
AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Shore Capital cheers Coiled Therapeutics dosing progress
Coiled Therapeutics fills two cohorts as reworked cancer drug advances
Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up
Sintana Energy advances deal to acquire KON-16 in Angola
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Ondine Biomedical strikes deal with Mexico's largest private hospital network
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
Metals One partner rejects claim that Barbrook mine deal has failed
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference